Inhibition of choline metabolism in an angioimmunoblastic T-cell lymphoma preclinical model reveals a new metabolic vulnerability as possible target for treatment.
Adrien KrugMarie TosoliniBlandine Madji HounoumJean-Jacques FourniéRoger GeigerMatteo PecoraroPatrick EmondPhilippe GaulardFrançois LemonnierJean-Ehrland RicciEls VerhoeyenPublished in: Journal of experimental & clinical cancer research : CR (2024)
Our results suggest that interfering with choline metabolism in AITL reveals a specific metabolic vulnerability and might represent a new therapeutic strategy for these patients.